MYCOF (Noveris Health Sciences) OCF Margin %: 0.00% (As of Mar. 2026)


MYCOF Noveris Health Sciences Inc MYCOF
23 GF Score
Price $2.00
GF Value $0.52
Valuation Significantly Overvalued
View Full Analysis

What is Noveris Health Sciences OCF Margin %?

Noveris Health Sciences MYCOF 23 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 23/100 and a GF Value™ of $0.52 (Significantly Overvalued). Among 959 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Noveris Health Sciences's Cash Flow from Operations for the three months ended in Mar. 2026 was $-0.21 Mil. Noveris Health Sciences's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Noveris Health Sciences's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Noveris Health Sciences's current OCF Yield % is -0.31%.

The historical rank and industry rank for Noveris Health Sciences's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Noveris Health Sciences was -1179.37%. The lowest was -343600.00%. And the median was -119691.27%.

MYCOF's OCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.95
* Ranked among companies with meaningful OCF Margin % only.

Noveris Health Sciences OCF Margin % Related Terms

Noveris Health Sciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Noveris Health Sciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noveris Health Sciences OCF Margin % Chart

Noveris Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -375,820.00 0.00 0.00 0.00 0.00

Noveris Health Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MYCOF
23GF Score
Noveris Health Sciences Inc MYCOF
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noveris Health Sciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Noveris Health Sciences's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0.007/0
= %

Noveris Health Sciences's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.207/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Noveris Health Sciences (MYCOF) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Noveris Health Sciences and its competitors. According to the industry distribution chart, Noveris Health Sciences ranks #999999 out of 959 companies in the Drug Manufacturers industry.
Is Noveris Health Sciences' OCF Margin % too high?
Noveris Health Sciences' current OCF Margin % is 0.00%. Based on the distribution chart, Noveris Health Sciences ranks #999999 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #999999 out of 959 companies for OCF Margin %. This places Noveris Health Sciences in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $2.00 — trading 284.6% above its estimated fair value. The current OCF Margin % is 0.00%. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noveris Health Sciences (MYCOF) Overvalued in 2026?

Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued. The current stock price of $2.00 is trading 284.6% above its estimated GF Value™ of $0.52. GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.

Key valuation signals for MYCOF:

  • OCF Margin %: 0.00%
  • GF Value™: $0.52 vs. price of $2.00 (284.6% above fair value)
  • GF Score™: 23/100

No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noveris Health Sciences Business Description

Other Exchanges 0NF1:GermanyNVRS:Canada
Address 1890 - 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score

Get the complete analysis for MYCOF

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$0.52
GF Value